Beyond CAR-T therapy for pleural mesothelioma: emerging CAR-NK, CAR-macrophage, CAR-γδ T, and CAR-NKT cell therapies
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor long-term outcomes and limited therapeutic options. Chimeric antigen receptor (CAR) T-cell therapy has shown promise in MPM, but its clinical efficacy remains constrained by poor tumor infiltration, an immunosuppressive tumor microenvironment (TME), cellular exhaustion, antigen heterogeneity, and treatment-related toxicity, as well as the logistical burden of autologous manufacturing. These limitations have motivated the development of alternative CAR platforms built on immune cell populations with distinct biological and therapeutic properties. In this review, we examine the preclinical and emerging clinical landscape of CAR-natural killer (CAR-NK), CAR-macrophage (CAR-M), CAR-γδ T-cell, and CAR-natural killer T-cell (CAR-NKT) therapies for MPM. We first discuss mesothelin (MSLN) and other tumor-associated antigens as candidate targets. We then evaluate how the biological attributes unique to each alternative effector population may address the limitations of conventional CAR-T therapy. We next examine strategies for allogeneic and “off-the-shelf” manufacturing, including the use of peripheral blood, cord blood, hematopoietic stem and progenitor cells, induced pluripotent stem cells, and established cell lines. Finally, we discuss next-generation engineering strategies, including cytokine armoring, immune checkpoint blockade, chemokine receptor engineering, and approaches to overcome host-versus-graft rejection. Collectively, current evidence supports CAR-NK, CAR-M, CAR-γδ T, and CAR-NKT cells as promising platforms for MPM, while underscoring the need for disease-specific preclinical validation and clinical investigation to determine how these approaches can be optimized for durable and safe therapeutic responses.
Authors
- Yan-Ruide Li (ORCID: https://orcid.org/0000-0002-9858-300X)
- Thomas Yuen (ORCID: https://orcid.org/0009-0001-7485-4186)
- Shelby Yeh (ORCID: https://orcid.org/0009-0001-6735-0780)
- Danna Marie Padua (ORCID: https://orcid.org/0009-0005-5397-7979)
- Coral Clune
- Nicklaus Chui
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12967-026-09262-z
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00